Top Qs
Timeline
Chat
Perspective
6-Hydroxy-DMT
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
6-Hydroxy-DMT, also known as 6-hydroxy-N,N-dimethyltryptamine, is a serotonin receptor modulator of the tryptamine family.[1][2][3][4][5] It is a major metabolite of the psychedelic drug dimethyltryptamine (DMT) in rodents but a minor metabolite of DMT in humans.[4][6][7] It is the 6-hydroxy analogue of DMT and a positional isomer of bufotenin (5-hydroxy-DMT) and psilocin (4-hydroxy-DMT).[2][3][8]
The drug was completely inactive in terms of psychoactive and autonomic effects at doses of 0.75 to 1 mg/kg (~53–70 mg for a 70-kb person) by intramuscular injection in humans.[1][2][5] The drug was said to be indistinguishable from placebo.[5] Conversely, DMT produced strong hallucinogenic effects at the same doses.[5] However, 6-hydroxy-DMT has been found to produce pharmacological effects in animals, albeit with diminished potency compared to DMT.[4][2][8][9] As examples, in terms of behavioral effects, 6-hydroxy-DMT was ≥3-fold less potent in rats, >10-fold less potent in cats, and 3-fold less potent in monkeys.[4] It was suggested by Richard Glennon and colleagues that the reduced activity of 6-hydroxy-DMT may be due to its greater hydrophilicity and reduced ability to penetrate the blood–brain barrier analogously to the case of bufotenin.[8]
Subsequent research assessed 6-hydroxy-DMT at the serotonin receptors in vitro.[7] It was found to have detectable but very low affinity for the serotonin 5-HT2 receptors (Ki ≥ 6,300–19,000 nM).[7]
6-Hydroxy-DMT was first described in the scientific literature by at least 1962.[10]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads